Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC101
- Development stage
- Unknown
- Lead developer
- HebeCell
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HC101 is an off-the-shelf, induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy developed by HebeCell using its proprietary ProtoNK™ platform. The therapy is designed to leverage the innate cytotoxic capabilities of NK cells to target and eliminate malignant cells and virus-infected cells without the need for patient-specific matching. HC101 is currently being evaluated in Phase 1 clinical trials for the treatment of various tumors and viral infections. The program includes specific variants such as HC101a, which is in preclinical development for pulmonary metastasis of pediatric sarcoma, and HC101b, which is being investigated for acute myeloid leukemia (AML).
- Other names
- ProtoNK NK cellsPSC-NK
Beyond the preview
Go deeper on HC101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC101.